JP7012970B2 - 神経損傷治療剤 - Google Patents
神経損傷治療剤 Download PDFInfo
- Publication number
- JP7012970B2 JP7012970B2 JP2019569589A JP2019569589A JP7012970B2 JP 7012970 B2 JP7012970 B2 JP 7012970B2 JP 2019569589 A JP2019569589 A JP 2019569589A JP 2019569589 A JP2019569589 A JP 2019569589A JP 7012970 B2 JP7012970 B2 JP 7012970B2
- Authority
- JP
- Japan
- Prior art keywords
- lascol
- nerve
- cells
- collagen
- atelocollagen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000028389 Nerve injury Diseases 0.000 title claims description 35
- 230000008764 nerve damage Effects 0.000 title claims description 35
- 108010045569 atelocollagen Proteins 0.000 claims description 75
- 108010035532 Collagen Proteins 0.000 claims description 72
- 102000008186 Collagen Human genes 0.000 claims description 72
- 229920001436 collagen Polymers 0.000 claims description 72
- 239000003814 drug Substances 0.000 claims description 37
- 229940124597 therapeutic agent Drugs 0.000 claims description 36
- 210000005036 nerve Anatomy 0.000 claims description 23
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 22
- 150000001413 amino acids Chemical group 0.000 claims description 18
- 210000000278 spinal cord Anatomy 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 15
- 239000004471 Glycine Substances 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 7
- 239000007857 degradation product Substances 0.000 claims description 6
- 210000004498 neuroglial cell Anatomy 0.000 claims description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 210000002569 neuron Anatomy 0.000 description 89
- 210000004027 cell Anatomy 0.000 description 45
- 238000000034 method Methods 0.000 description 40
- 239000000243 solution Substances 0.000 description 37
- 239000000463 material Substances 0.000 description 34
- 210000003050 axon Anatomy 0.000 description 33
- 102000004190 Enzymes Human genes 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 30
- 229940088598 enzyme Drugs 0.000 description 30
- 238000010186 staining Methods 0.000 description 23
- 239000007864 aqueous solution Substances 0.000 description 20
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 20
- 238000004113 cell culture Methods 0.000 description 18
- 150000003839 salts Chemical class 0.000 description 17
- 241000700159 Rattus Species 0.000 description 14
- 239000004365 Protease Substances 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 101100328884 Caenorhabditis elegans sqt-3 gene Proteins 0.000 description 12
- 102000004243 Tubulin Human genes 0.000 description 12
- 108090000704 Tubulin Proteins 0.000 description 12
- 210000001130 astrocyte Anatomy 0.000 description 12
- 208000036815 beta tubulin Diseases 0.000 description 12
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 12
- 210000000020 growth cone Anatomy 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- 238000012258 culturing Methods 0.000 description 10
- 238000000354 decomposition reaction Methods 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 238000003776 cleavage reaction Methods 0.000 description 8
- 235000019688 fish Nutrition 0.000 description 8
- 210000002241 neurite Anatomy 0.000 description 8
- 230000007017 scission Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 6
- 108010022452 Collagen Type I Proteins 0.000 description 6
- 102100023206 Neuromodulin Human genes 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 210000005056 cell body Anatomy 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 102000005927 Cysteine Proteases Human genes 0.000 description 5
- 108010005843 Cysteine Proteases Proteins 0.000 description 5
- 229930040373 Paraformaldehyde Natural products 0.000 description 5
- 102000035195 Peptidases Human genes 0.000 description 5
- 108091005804 Peptidases Proteins 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 229920002866 paraformaldehyde Polymers 0.000 description 5
- 235000019419 proteases Nutrition 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 208000020431 spinal cord injury Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241000972773 Aulopiformes Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- 241000276707 Tilapia Species 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 210000004126 nerve fiber Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 235000019515 salmon Nutrition 0.000 description 4
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108010004032 Bromelains Proteins 0.000 description 3
- 108090000625 Cathepsin K Proteins 0.000 description 3
- 102000004171 Cathepsin K Human genes 0.000 description 3
- 208000025962 Crush injury Diseases 0.000 description 3
- 241000252233 Cyprinus carpio Species 0.000 description 3
- 108090000270 Ficain Proteins 0.000 description 3
- 241000270322 Lepidosauria Species 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 235000019835 bromelain Nutrition 0.000 description 3
- 210000003855 cell nucleus Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000001000 micrograph Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 230000014511 neuron projection development Effects 0.000 description 3
- 235000019834 papain Nutrition 0.000 description 3
- 229940055729 papain Drugs 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000001878 scanning electron micrograph Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000012453 sprague-dawley rat model Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 101800000263 Acidic protein Proteins 0.000 description 2
- ZAINTDRBUHCDPZ-UHFFFAOYSA-M Alexa Fluor 546 Chemical compound [H+].[Na+].CC1CC(C)(C)NC(C(=C2OC3=C(C4=NC(C)(C)CC(C)C4=CC3=3)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=C2C=3C(C(=C(Cl)C=1Cl)C(O)=O)=C(Cl)C=1SCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O ZAINTDRBUHCDPZ-UHFFFAOYSA-M 0.000 description 2
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000712 Cathepsin B Proteins 0.000 description 2
- 102000004225 Cathepsin B Human genes 0.000 description 2
- 108090000619 Cathepsin H Proteins 0.000 description 2
- 102000004175 Cathepsin H Human genes 0.000 description 2
- 108090000624 Cathepsin L Proteins 0.000 description 2
- 102000004172 Cathepsin L Human genes 0.000 description 2
- 108090000613 Cathepsin S Proteins 0.000 description 2
- 102100035654 Cathepsin S Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 241000269841 Thunnus albacares Species 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019836 ficin Nutrition 0.000 description 2
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 2
- 238000002073 fluorescence micrograph Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000002518 glial effect Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003505 heat denaturation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- MLFHJEHSLIIPHL-UHFFFAOYSA-N isoamyl acetate Chemical compound CC(C)CCOC(C)=O MLFHJEHSLIIPHL-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 239000000696 magnetic material Substances 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 210000000578 peripheral nerve Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 241000252073 Anguilliformes Species 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101710155556 Calcium-dependent protease Proteins 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010061431 Glial scar Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 101000876511 Homo sapiens General transcription and DNA repair factor IIH helicase subunit XPD Proteins 0.000 description 1
- 101000616778 Homo sapiens Myelin-associated glycoprotein Proteins 0.000 description 1
- 101000979249 Homo sapiens Neuromodulin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100027996 Mus musculus Omg gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 101710144282 Neuromodulin Proteins 0.000 description 1
- 108010077641 Nogo Proteins Proteins 0.000 description 1
- 102000010410 Nogo Proteins Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004813 Perfluoroalkoxy alkane Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 241001482311 Trionychidae Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108090000350 actinidain Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000009933 burial Methods 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000971 hippocampal effect Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 229940117955 isoamyl acetate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012913 medium supplement Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 208000022084 motor paralysis Diseases 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 230000005709 nerve cell growth Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 210000003757 neuroblast Anatomy 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 229920011301 perfluoro alkoxyl alkane Polymers 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M3/00—Tissue, human, animal or plant cell, or virus culture apparatus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0619—Neurons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Virology (AREA)
- Sustainable Development (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Description
LASColを含む神経損傷治療剤であって、
前記LASColは、コラーゲンまたはアテロコラーゲンのトリプルヘリカルドメインの下記(A)に示されるアミノ末端のアミノ酸配列においてα1鎖においてY 1 とY 2 との間の化学結合が切断されている若しくは、下記(B)に示されるアミノ末端のアミノ酸配列においてα2鎖のGとX 3 との間の化学結合切断されているコラーゲンまたはアテロコラーゲンの分解物を含む、神経損傷治療剤である。
(A)-Y 1 -Y 2 -Y 3 -G-Y 4 -Y 5 -G-Y 6 -Y 7 -G-Y 8 -Y 9 -G-(配列番号1);
(但し、Gはグリシンであり、Y 1 ~Y 9 は、任意のアミノ酸である)
(B)-G-X 1 -X 2 -G-X 3 -X 4 -G-X 5 -X 6 -G-(配列番号2);
(但し、Gはグリシンであり、X 1 ~X 6 は、任意のアミノ酸である)
(A)-Y1-Y2-Y3-G-Y4-Y5-G-Y6-Y7-G-Y8-Y9-G-(配列番号1);
(但し、Gは、グリシンであり、Y1~Y9は、任意のアミノ酸である)。
(但し、Gは、グリシンであり、X1~X6は、任意のアミノ酸である)。これをLASCol-Bと呼ぶ。LASCol-Bは、トリプルヘリカルドメインの内側で切断が生じている。配列番号2番では「-G-X1-X2-G-」のGがトリプルヘリカルドメインのN末端側のグリシンである。もちろん、他のペプチドが含まれるLASColもあり得る。神経細胞の生存維持および突起伸長が行われる点でLASCol-Aは、現在知られているLASCol中で最も好適である。しかし、他のLASColを排除するものではない。
LASColの材料になるコラーゲンまたはアテロコラーゲンは、特に限定されず、周知のコラーゲンおよびアテロコラーゲンであればよい。
(i)高濃度の塩の存在下にて、コラーゲンまたはアテロコラーゲンと、酵素とを接触させる方法。
(ii)高濃度の塩と接触させた後の酵素と、コラーゲンまたはアテロコラーゲンとを接触させる方法。
(iii)低濃度の塩の存在下にて、コラーゲンまたはアテロコラーゲンと、酵素とを接触させる方法。
塩化ナトリウムの濃度が0mMと1500mMである50mMクエン酸緩衝液(pH3.0)を準備した。なお、当該水溶液の溶媒として、水を用いた。
上記のようにして作製したLASCol溶液を用いて神経細胞の生存維持能について確認した。24ウェルマイクロプレートにLASCol、アテロコラーゲン、ポリ-L-リシン(以下「PLL」ともいう。)をコートした。なお、コントロールとして何もコートしていないNon-coatedのウェルも用意した。これらのウェルに新生仔ラット海馬由来神経細胞(間葉系幹細胞ではなく、分化が終了した神経細胞、以下単に「神経細胞」と呼ぶ。)をNeurobasal medium/B-27 supplement(Thermo Fisher Scientific社製、以下「NB/B27」と呼ぶ)に懸濁して、播種した。
(1)アストロサイト
LASCol上でアストロサイトの培養を試みた場合の結果を示す。96ウェルマイクロプレートにLASColおよびアテロコラーゲンをコートした。コントロール群としてNon-coatedも用意した。次にラット大脳由来のアストロサイトを3×104、1×105個/mLで播種し、48時間後にWST-1法で細胞数を測定した。WST-1法は、比色定量法MTT法の一つである。MTT法は、MTTや類似の色素をホルマザン色素(紫色)へ還元する酵素活性を測定する比色定量法である。
LASCol溶液、アテロコラーゲン溶液、PLL溶液を塗布し、Mesenchymal Stem Cell Basal Medium/MSCGM SingleQuots(Lonza社製)を加えたディッシュ上に骨髄間質細胞を3×103個/mlの濃度で播種し、7日後に観察を行った。結果を図11に示す。図11(a)は、LASCol溶液を塗布したもの(LASColコート群)であり、図11(b)はアテロコラーゲン溶液を塗布したもの(アテロコラーゲンコート群)であり、図11(c)はPLL溶液を塗布したもの(ポリ-L-リシンコート群:PLLコート群)であり、図11(d)はノンコートのもの(Non-coated、コントロール群)である。なお、写真中右下のスケール線は100μmに相当する。図11(a)のLASColコート群では、細い紡錘形の細胞体から突起が伸びているものが散見された。これが骨髄間質細胞である。細胞の密度は10%程度である。
LASCol上でマクロファージの培養を試みた場合の結果を示す。8ウェルチャンバーにLASColまたはアテロコラーゲンをコートした。次にラット腹腔マクロファージを2×105個/mL播種した。48時間後に観察した。図13に結果を示す。
以上のようにin vitroにおいて、LASColコート群では、神経細胞は好適に培養されると考えられる。この効果が生体内でも発揮されれば、神経細胞の再生にとって、有用な薬剤となり得る。そこで、LASColの生体内での神経細胞培養能を調べた。
9週齢の雌のSprague-Dawley(SD)ラットを用いた。後述する各群は7匹ずつで構成した。圧挫損傷は、標準的なニューヨーク大学の重量落下装置を使用した。装置の条件は、10g、落下高さ7.5cmである。与えた衝撃は1回とした。
タンパク質)に対する抗体で染色した。
Claims (4)
- LASColを含む神経損傷治療剤であって、
前記LASColは、コラーゲンまたはアテロコラーゲンのトリプルヘリカルドメインの下記(A)に示されるアミノ末端のアミノ酸配列においてα1鎖においてY 1 とY 2 との間の化学結合が切断されている若しくは、下記(B)に示されるアミノ末端のアミノ酸配列においてα2鎖のGとX 3 との間の化学結合切断されているコラーゲンまたはアテロコラーゲンの分解物を含む、神経損傷治療剤。
(A)-Y 1 -Y 2 -Y 3 -G-Y 4 -Y 5 -G-Y 6 -Y 7 -G-Y 8 -Y 9 -G-(
配列番号1);
(但し、Gはグリシンであり、Y 1 ~Y 9 は、任意のアミノ酸である)
(B)-G-X 1 -X 2 -G-X 3 -X 4 -G-X 5 -X 6 -G-(配列番号2);
(但し、Gはグリシンであり、X 1 ~X 6 は、任意のアミノ酸である) - 前記LASColは乾燥されていることを特徴とする請求項1に記載された神経損傷治療剤。
- グリア細胞の増殖を抑制する請求項1または2の何れかの請求項に記載された神経損傷治療剤。
- 前記神経が脊髄であることを特徴とする請求項1乃至3の何れか一の請求項に記載された神経損傷治療剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018015496 | 2018-01-31 | ||
JP2018015496 | 2018-01-31 | ||
PCT/JP2019/003502 WO2019151450A1 (ja) | 2018-01-31 | 2019-01-31 | 神経細胞培養材および神経損傷治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2019151450A1 JPWO2019151450A1 (ja) | 2021-01-28 |
JP7012970B2 true JP7012970B2 (ja) | 2022-01-31 |
Family
ID=67478298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019569589A Active JP7012970B2 (ja) | 2018-01-31 | 2019-01-31 | 神経損傷治療剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20210047385A1 (ja) |
JP (1) | JP7012970B2 (ja) |
CN (1) | CN111868226A (ja) |
WO (1) | WO2019151450A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007177074A (ja) | 2005-12-28 | 2007-07-12 | Tohoku Univ | 組成物およびその製造方法 |
WO2015167004A1 (ja) | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | 分化誘導用組成物 |
WO2015167003A1 (ja) | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | コラーゲンまたはアテロコラーゲンの分解物、当該分解物の製造方法、および、当該分解物の利用 |
-
2019
- 2019-01-31 WO PCT/JP2019/003502 patent/WO2019151450A1/ja active Application Filing
- 2019-01-31 JP JP2019569589A patent/JP7012970B2/ja active Active
- 2019-01-31 CN CN201980011059.1A patent/CN111868226A/zh active Pending
- 2019-01-31 US US16/966,232 patent/US20210047385A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007177074A (ja) | 2005-12-28 | 2007-07-12 | Tohoku Univ | 組成物およびその製造方法 |
WO2015167004A1 (ja) | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | 分化誘導用組成物 |
WO2015167003A1 (ja) | 2014-04-30 | 2015-11-05 | 学校法人近畿大学 | コラーゲンまたはアテロコラーゲンの分解物、当該分解物の製造方法、および、当該分解物の利用 |
Also Published As
Publication number | Publication date |
---|---|
US20210047385A1 (en) | 2021-02-18 |
JPWO2019151450A1 (ja) | 2021-01-28 |
CN111868226A (zh) | 2020-10-30 |
WO2019151450A1 (ja) | 2019-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chowdhury et al. | Collagen type I: A versatile biomaterial | |
Zhang et al. | A nerve graft constructed with xenogeneic acellular nerve matrix and autologous adipose-derived mesenchymal stem cells | |
ES2258255T3 (es) | Composiciones destinadas a la reparacion y la regeneracion de la duramadre humana. | |
US8663675B2 (en) | Injectable matrix having a polymer and a stem cell niche composed of cup-shaped nanoparticles containing growth factors or physiological agents for organ reconstruction | |
DE60026586T2 (de) | Zellulare matrix | |
DE60003580T2 (de) | MEDIZINISCHE VORRICHTUNG mit nukleinsäurehaltiger synthetischer Oberfläche zur in-vivo Induktion seiner Endothelialisierung | |
JP5607176B2 (ja) | 新規ペプチドおよびその用途 | |
CN107224617B (zh) | 一种以脾脏细胞外基质为原料的水凝胶及其制备方法 | |
Yan et al. | Use new PLGL-RGD-NGF nerve conduits for promoting peripheral nerve regeneration | |
CA2572964A1 (en) | Purified amphiphilic peptide compositions and uses thereof | |
Kim et al. | Acceleration of peripheral nerve regeneration through asymmetrically porous nerve guide conduit applied with biological/physical stimulation | |
JP2020089759A (ja) | 骨間隙を充填するための材料および方法 | |
Nomura et al. | Delayed implantation of intramedullary chitosan channels containing nerve grafts promotes extensive axonal regeneration after spinal cord injury | |
Wang et al. | A synthetic oxygen carrier in fibrin matrices promotes sciatic nerve regeneration in rats | |
CN102665775A (zh) | 诱导硬组织再生的材料 | |
Yang et al. | A hyaluronic acid granular hydrogel nerve guidance conduit promotes regeneration and functional recovery of injured sciatic nerves in rats | |
US20200390526A1 (en) | Method for manufacturing complex for bone grafting and complex for bone grafting manufactured thereby | |
EP2473193A1 (en) | Methods of engineering neural tissue | |
JP6984829B2 (ja) | 椎間板変性の治療剤および椎間板細胞培養材 | |
JP7012970B2 (ja) | 神経損傷治療剤 | |
JP2010088625A (ja) | 人工弁 | |
Arda et al. | Can a small intestine segment be an alternative biological conduit for peripheral nerve regeneration? | |
US20170021056A1 (en) | Peptide amphiphile biomaterials for nerve repair | |
Guo et al. | Self-assembling peptides mediate neural regeneration | |
KR100644078B1 (ko) | 양막과 생분해성 고분자로 구성된 이식용 진피대체물,이의 제조방법 및 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200716 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210903 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20211117 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20211117 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211222 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220111 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7012970 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |